Background: Dexmedetomidine, a highly selective alpha(2)-adrenergic ag
onist, increases perioperative hemodynamic stability in healthy patien
ts but decreases blood pressure and heart rate. The goal of this study
was to evaluate, in a preliminary manner, the hemodynamic effects of
perioperatively administered dexmedetomidine in surgical patients at h
igh risk for coronary artery disease. Methods: Twenty-four vascular su
rgery patients received a continuous infusion of placebo or one of thr
ee doses of dexmedetomidine, targeting plasma concentrations of 0.15 n
g/ml (low dose), 0.30 ng/ml (medium dose), or 0.45 ng/ml (high dose) f
rom 1 h before induction of anesthesia until 48 h postoperatively. All
patients received standardized anesthesia and hemodynamic management.
Blood pressure, heart rate, and Holter ECG were monitored; additional
monitoring included continuous 12-lead ECG preoperatively, anesthetic
concentrations and myocardial wall motion (echocardiography) intraope
ratively, and cardiac enzymes postoperatively. Results: Preoperatively
, there was a decrease in heart rate (low dose 11%, medium dose 5%, hi
gh dose 20%) and systolic blood pressure (low dose 3%, medium dose 12%
, high dose 20%) in patients receiving dexmedetomidine. Intraoperative
ly, dexmedetomidine groups required more vasoactive medications to mai
ntain hemodynamics within predetermined limits. Postoperatively, dexme
detomidine groups had less tachycardia (minutes/monitored hours) than
the placebo group (placebo 23 min/h; low dose 9 min/h, P = 0.006; medi
um dose 0.5 min/h, P = 0.004; high dose 2.3 min/h, P = 0.004). Bradyca
rdia was rare in all groups, There were no myocardial infarctions or d
iscernible trends in the laboratory results. Conclusions: Infusion of
dexmedetomidine up to a targeted plasma concentration of 0.45 ng/ml ap
pears to benefit perioperative hemodynamic management of surgical pati
ents undergoing vascular surgery but required greater intraoperative p
harmacologic intervention to support blood pressure and heart rate.